MA29969B1 - Formulations de quinolinones - Google Patents

Formulations de quinolinones

Info

Publication number
MA29969B1
MA29969B1 MA30953A MA30953A MA29969B1 MA 29969 B1 MA29969 B1 MA 29969B1 MA 30953 A MA30953 A MA 30953A MA 30953 A MA30953 A MA 30953A MA 29969 B1 MA29969 B1 MA 29969B1
Authority
MA
Morocco
Prior art keywords
compound
quinolinones
formulations
tautomer
salt
Prior art date
Application number
MA30953A
Other languages
English (en)
Inventor
Joyce Chou
Augustus Okhamafe
Patricia Frech
Rampurma Gullapalli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29969B1 publication Critical patent/MA29969B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE FORMULATION PHARMACEUTIQUE COMPRENANT : UN COMPOSÉ DE FORMULE (I), UN TAUTOMÈRE DU COMPOSÉ, UN SEL DU COMPOSÉ, UN SEL DU TAUTOMÈRE OU UN MÉLANGE DE CEUX-CI ET AU MOINS UN INGRÉDIENT CHOISI DANS LE GROUPE COMPRENANT (I) LA CELLULOSE ; (II) LE DIOXYDE DE SILICIUM ; (III) LE STÉARATE DE MAGNÉSIUM ; ET (IV) UN INGRÉDIENT CHOISI PARMI LA CROSPOVIDONE, L'AMIDON ET LE LACTOSE.
MA30953A 2005-11-29 2008-05-20 Formulations de quinolinones MA29969B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74057705P 2005-11-29 2005-11-29
US74131705P 2005-12-01 2005-12-01

Publications (1)

Publication Number Publication Date
MA29969B1 true MA29969B1 (fr) 2008-11-03

Family

ID=38024178

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30953A MA29969B1 (fr) 2005-11-29 2008-05-20 Formulations de quinolinones

Country Status (23)

Country Link
US (2) US20080293738A1 (fr)
EP (2) EP2772257A1 (fr)
JP (1) JP2009517481A (fr)
KR (1) KR20080074143A (fr)
CN (1) CN102670530A (fr)
AR (1) AR062545A1 (fr)
AU (1) AU2006320591B2 (fr)
BR (1) BRPI0619370A2 (fr)
CA (1) CA2627544C (fr)
CL (1) CL2010000387A1 (fr)
EC (1) ECSP088467A (fr)
ES (1) ES2467162T3 (fr)
IL (1) IL190865A0 (fr)
MA (1) MA29969B1 (fr)
MY (1) MY148529A (fr)
NO (1) NO20082938L (fr)
NZ (1) NZ567550A (fr)
PE (1) PE20070760A1 (fr)
PL (1) PL1957074T3 (fr)
PT (1) PT1957074E (fr)
RU (1) RU2433826C2 (fr)
TW (1) TW200730176A (fr)
WO (1) WO2007064719A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR070924A1 (es) * 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
WO2010068311A1 (fr) 2008-05-23 2010-06-17 Amira Pharmaceuticals, Inc. Inhibiteur de la protéine d’activation de 5-lipoxygénase
JP2011526928A (ja) * 2008-07-03 2011-10-20 ノバルティス アーゲー 溶融造粒方法
UY33472A (es) * 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
WO2013063003A1 (fr) 2011-10-28 2013-05-02 Novartis Ag Méthode de traitement des tumeurs stromales gastro-intestinales
CA2861377A1 (fr) 2012-01-31 2013-08-08 Novartis Ag Combinaison d'un inhibiteur de rtk avec un anti-oestrogene et son utilisation pour traiter le cancer
JP2015522070A (ja) 2012-07-11 2015-08-03 ノバルティス アーゲー 消化管間質腫瘍を治療する方法
WO2014058785A1 (fr) 2012-10-10 2014-04-17 Novartis Ag Polythérapie
TWI535784B (zh) 2014-08-26 2016-06-01 財團法人工業技術研究院 剪切增稠配方、及包含其之複合材料
WO2020115676A1 (fr) 2018-12-06 2020-06-11 Glaxosmithkline Intellectual Property Development Limited Nouvelle formulation pharmaceutique

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663606A (en) * 1966-06-21 1972-05-16 Mitsui Toatsu Chemicals Organic imino-compounds
DE2363459A1 (de) 1973-12-20 1975-06-26 Basf Ag Neue fluoreszierende chinolinverbindungen
US4119105A (en) 1977-01-31 1978-10-10 Olin Corporation Air flow limiting filter
JPH0699497B2 (ja) 1987-04-16 1994-12-07 富士写真フイルム株式会社 光重合性組成物
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JP3161780B2 (ja) 1991-09-30 2001-04-25 東レ・ダウコーニング・シリコーン株式会社 α，ω−ジヒドロキシフルオロアルキルメチルポリシロキサンの製造方法
JP3142378B2 (ja) 1992-06-22 2001-03-07 ティーディーケイ株式会社 有機ｅｌ素子
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
JPH0743896A (ja) 1993-07-28 1995-02-14 Toyobo Co Ltd 光重合性組成物
JPH0829973A (ja) 1994-07-11 1996-02-02 Toyobo Co Ltd 光重合性組成物
JP3441246B2 (ja) 1995-06-07 2003-08-25 富士写真フイルム株式会社 光重合性組成物
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6010711A (en) * 1996-01-26 2000-01-04 University Of Rochester Methods, articles and compositions for the pharmacologic inhibition of bone resorption with phosphodiesterase inhibitors
US6514971B1 (en) 1996-03-15 2003-02-04 Zeneca Limited Cinnoline derivatives and use as medicine
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
EP0912549A4 (fr) 1996-06-20 2002-01-02 Univ Texas Composes et procedes d'obtention de preparations pharmacologiquement actives et leurs utilisations
AU733551B2 (en) 1996-09-25 2001-05-17 Astrazeneca Ab Qinoline derivatives inhibiting the effect of growth factors such as VEGF
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
JP4959049B2 (ja) 1997-08-22 2012-06-20 アストラゼネカ・ユーケイ・リミテッド 血管新生阻害剤としてのオキシインドリルキナゾリン誘導体
CA2328893A1 (fr) 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs de l'activite du facteur de croissance endothelial vasculaire (vegf)
US6138605A (en) 1998-08-05 2000-10-31 Seascape Systems Limited Access and evacuation apparatus with articulated arm
DE19841985A1 (de) 1998-09-03 2000-03-09 Schering Ag Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
IL126953A0 (en) 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
WO2001052875A1 (fr) 2000-01-18 2001-07-26 Ludwig Institute For Cancer Research Inhibiteur peptidomimetique de vegf-d/vegf-c/vegf
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
CA2397919A1 (fr) 2000-01-19 2001-07-26 Parkash S. Gill Compositions renfermant des oligonucleotides antisens diriges contre le vegf et methodes associees
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
HU230315B1 (hu) * 2000-03-07 2016-01-28 Rush-Presbyterian-St. Luke's Medical Center Összetételek és eljárások patogén mikrobák és spermatozoák csapdázására
PT1313734E (pt) 2000-09-01 2010-02-09 Novartis Vaccines & Diagnostic Derivados aza heterocíclicos e sua utilização terapêutica
DK1650203T3 (da) 2000-09-11 2008-06-02 Novartis Vaccines & Diagnostic Quinolinonderivater som tyrosinkinaseinhibitorer
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
WO2004018419A2 (fr) 2002-08-23 2004-03-04 Chiron Corporation Quinolinones de benzimidazole et leurs utilisations
SG148864A1 (en) 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
JP4823914B2 (ja) 2003-11-07 2011-11-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｆｇｆｒ３の阻害および多発性骨髄腫の治療
CN1960731B (zh) * 2004-02-20 2011-12-07 诺华疫苗和诊断公司 调节炎性和转移过程的方法
WO2006122950A1 (fr) * 2005-05-18 2006-11-23 M & G Polimeri Italia S.P.A. Composition polyester
SG154451A1 (en) * 2005-05-23 2009-08-28 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1- yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts

Also Published As

Publication number Publication date
NZ567550A (en) 2011-08-26
RU2433826C2 (ru) 2011-11-20
CA2627544A1 (fr) 2007-06-07
PE20070760A1 (es) 2007-10-04
EP1957074B1 (fr) 2014-03-19
EP1957074A2 (fr) 2008-08-20
WO2007064719A3 (fr) 2007-08-16
ECSP088467A (es) 2008-06-30
MY148529A (en) 2013-04-30
BRPI0619370A2 (pt) 2011-09-27
JP2009517481A (ja) 2009-04-30
US20080293738A1 (en) 2008-11-27
AR062545A1 (es) 2008-11-19
KR20080074143A (ko) 2008-08-12
AU2006320591B2 (en) 2010-06-03
CN102670530A (zh) 2012-09-19
NO20082938L (no) 2008-06-30
CL2010000387A1 (es) 2010-08-06
AU2006320591A1 (en) 2007-06-07
ES2467162T3 (es) 2014-06-12
EP2772257A1 (fr) 2014-09-03
US20120276200A1 (en) 2012-11-01
RU2008126384A (ru) 2010-01-10
TW200730176A (en) 2007-08-16
WO2007064719A2 (fr) 2007-06-07
PL1957074T3 (pl) 2014-08-29
PT1957074E (pt) 2014-06-25
CA2627544C (fr) 2015-07-07
IL190865A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
MA29969B1 (fr) Formulations de quinolinones
BR0214164A (pt) Ligantes do receptor canabinóide
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
BR0207583A (pt) Derivados de poliamida possuindo atividade antibacteriana, antifungo ou antitumor
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
WO2003084943A3 (fr) Derives de terphenyle, leur preparation, les compositions pharmaceutiques en contenant
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
CA2534798A1 (fr) Utilisation de derives du thiazole comme modulateurs des recepteurs cannabinoides
MA30778B1 (fr) Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques
EE200200207A (et) Kinoliiniderivaatide kasutamine vähivastase ravimi valmistamiseks, ühendite saamine ning neid sisaldavad farmatseutilised kompositsioonid
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
PH12014500937A1 (en) 5-ht 1a receptor substype agonist
NO20062019L (no) P-glykoproteininhibitor, fremgangsmater for fremstilling av denne samt farmasoytiske preparater inneholdende den samme
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
BR0210028A (pt) Agentes antibacterianos
MA27129A1 (fr) Les pyrrolopyrimidines en tant qu'inhibiteurs du kinase de proteine.
MA27501A1 (fr) Derives d'imidazoquinoline en tant que ligands recepteurs de l'adenosine a3
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
NO20032261L (no) Medisinske preparater
WO2005058890A3 (fr) Derives d'hydronopol utilises comme agonistes des recepteurs orl1 humains